Jubilant Life Sciences has received approval from the US health regulator for Telmisartan tablets, used for the treatment of hypertension, in the American market.
In a BSE filing, the company said “it has received Abbreviated New Drug Application (ANDA) final approval for Telmisartan tablets, USP 20,40 and 80mg, the generic version of Micardis tablets of Boehringer Ingelheim Pharmaceuticals Inc.’’
As on June 30, 2016, Jubilant Life Sciences had 770 filings for oral solids of which 578 have been approved in various regions globally.
“This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe,” it said.
Shares of Jubilant Life Sciences ended up by 0.67 per cent at Rs 508 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.